Fig. 6
From: Oral splicing modulator branaplam in Huntington’s disease: a phase 2 randomized controlled trial
Percentage change from baseline in CSF mHTT levels over time (safety analysis set). Data show mean percent change from baseline over time in mHTT protein levels in CSF. Error bars represent standard errors.
